（1）国家自然科学基金委员会，青年项目，82303869，KRAS(G12D)突变通过视神经蛋白 (OPTN)负向调控线粒体自噬导致卵巢癌免疫治疗抵抗的机制研究，2024-01-01 至 2026-12-31, 30万元, 在 研, 主持

（2）上海市科技委员会, 上海市2023年度“科技创新行动计划”启明星项目申报指南 / 启明星培育(扬帆 专项), 23YF1433400, 靶向RB1阳性卵巢癌的新型策略研究, 2024-04 至 2026-03, 20万元, 在研, 主持

（3）同济大学，附属妇产科医院, 院级课题, 2022RC08, CDK4/6抑制剂联合治疗卵巢癌的新型策略研究, 2022-11 至 2025-11, 50万元, 在研, 主持

（1）国家自然科学基金委员会，青年项目，82303869，KRAS(G12D)突变通过视神经蛋白 (OPTN)负向调控线粒体自噬导致卵巢癌免疫治疗抵抗的机制研究，2024-01-01 至 2026-12-31, 30万元, 在研, 主持

（2）上海市科技委员会, 上海市2023年度“科技创新行动计划”启明星项目申报指南 / 启明星培育(扬帆专项), 23YF1433400, 靶向RB1阳性卵巢癌的新型策略研究, 2024-04 至 2026-03, 20万元, 在研, 主持

（3）同济大学，附属妇产科医院, 院级课题, 2022RC08, CDK4/6抑制剂联合治疗卵巢癌的新型策略研究,2022-11 至 2025-11, 50万元, 在研, 主持

一、（代表性论著:#Co-corresponding）

(1) Jindan Sheng; Susumu Kohno; Nobuhiro Okada; Nobuyuki Okahashi; Kana Teranishi; FumioMatsuda; Hiroshi Shimizu; Paing Linn; Naoko Nagatani; Minako Yamamura; Kenichi Harada; Shin-ichiHorike; Hiroshi Inoue; Seiji Yano; Sharad Kumar; Shunsuke Kitajima; Itsuki Ajioka; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-DependentKinase 4/6 Inhibitor Combination Therapy, HEPATOLOGY, 2021, 74(4): 1971-1993.IF=17.298

(2) Chen Chu;Shanshan Zheng;NingMitchell;Zheqi Li;Xiaowei Wu;Tian Zhang;Fabin Dang;Wojciech Michowski;Miranda L. Xu; Aleksandra Kolodziejczyk;Joao Paulo; Xixi Zhang;Krzysztof Kotowski;DiegoMartinez-Alonso;Jane A. Kirby;Finn Groezinger;Yubin Zhou;Miao He;Yoshinaga Ito;Anushree C. Gulvady, Pierre Foidart, Jun Nishida,Xiaohan Ning, Yu Zhou, Jindan Sheng,Samanta Sharma;Jan M. Suski;Anne Fassl,Yan Geng, Wenyi Wei, Steven P Gygi,Kornelia Polyak, Kai W Wucherpfennig, Piotr Sicinski*.CDK2 kinase inhibition promotes PD-L1 transcription through BRD4 andsynergizes with immune checkpoint blockade,Nature, 2024,in revision.IF=50.5

(3) Paing Linn; Susumu Kohno; Jindan Sheng; Nilakshi Kulathunga; Hai Yu; Zhiheng Zhang;Dominic Voon; Yoshihiro Watanabe; Chiaki Takahashi ; Targeting RB1 Loss in Cancers, cancers,2021, 13(15): 3737.IF=6.575 

(4) Mingjun Ma; Chao Wang; Meixuan Wu; Sijia Gu; Jiani Yang; Yue Zhang; Shanshan Cheng;Shilin Xu; Minghai Zhang; Yongsong Wu; Yaqian Zhao; Xiu Tian; Dominic Chih-Cheng Voon; ChiakiTakahashi; Jindan Sheng#; Yu Wang# .CSGALNACT2 restricts ovarian cancer migration and invasion bymodulating MAPK/ERK pathway through DUSP1, Cellular Oncology, 2023, 903(9): 13402.IF=6.6

(5) Xiaomei Luo; Yingjie Wang; Hao Zhang; Guangquan Chen; Jindan Sheng; Xiu Tian; Renhao Xue;Yu Wang .Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-RelatedGenes Suggesting a Potential Role for FBXO9, Biomolecules, 2023, 13(12): 1724.IF=4.8

(6) Jiani Yang; Chao Wang; Yue Zhang; Shanshan Cheng; Meixuan Wu; Sijia Gu; Shilin Xu;Yongsong Wu; Jindan Sheng; Dominic Chih-Cheng Voon; Yu Wang.Clinical significance and immuneinfiltration analyses of a novel coagulation-related signature in ovarian cancer, Cancer Cell International, 2023, 23(1).IF=5.3

二、专利:

(1) 高橋 智聡; 河野 晋; 盛金丹 ; RB1陽性癌の治療用医薬組成物及びキット, 2020-10-28, 日本,特願2020-180429 (专利)

(2) 王育; 盛金丹; 顾思佳; 吴美璇 ; 一种治疗 kras 突变的卵巢癌的组合药物及其应用, 2023-5-31,中国, 202310374305.8 (专利)

(3) 王育; 盛金丹; 张越; 汪超 ; 一种治疗 CCNE1 异常扩增型卵巢癌的药物组合物及其应用, 2023-12-6, 中国, 202311658341.3 (专利)

(4) 王育; 盛金丹; 吴美璇; 顾思佳 ; 一种治疗 RB1 阳性的卵巢癌的组合药物及其应用, 2023-6-6, 中国, 202310374279.9 (专利)

三、参加或组织的学术会议

（1）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, The 43rd Annual Meetingof the Molecular Biology Society of Japan (MBSJ2020 Online) , 线上, 2020-12-2至2020-12-4 (会议报告)

（2）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, 2021 the JapaneseSociety of Medical Oncology Annual Meeting (JSMO2021), 线上, 2021-2-18至2021-2-21 (会议报告)

（3）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, AACR ANNUAL MEETING2021 2021/4/10-2021/4/15, 线上, 2021-4-10至2021-4-15 (会议报告)

（4）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, The 80th Annual Meetingof the Japanese Cancer Association 2021/09/30-2021/10/02, 线上, 2021-9-30至2021-10-2 (会议报告)

（5）Jindan Sheng; Dominic Voon; Yoshihiro Watanabe; Chiaki Takahashi；Yu Wang; Gynecologic Oncology Symposium，2023,上海市第一妇婴保健院行政楼308室.

（6）Jindan Sheng; Cancer Biology Retreat 2024，Broad Institute of MIT and Harvard，Dana-Farber Cancer Institute; Department of Cancer Biology.

（7）MGH Molecular Biology & HMS Genetics 2024， Omni Mount Washington Hotel Bretton Woods, NH Massachusetts General Hospital and Harvard Medical School.

四、学术奖励

（1） Jindan Sheng(1/1); A targetable NF-κB−LCN2 axis controls liver tumorigenesis, 中国驻日本大使馆, 其他, 国际学术奖, 2022(Jindan Sheng) (科研奖励)

（2）盛金丹(1/1); 肝細胞がんの分子機序解明と新規治療法開発, 日本学政, 其他, 其他, 2021(盛金丹) (科研奖励)

1.Medical Tribune(https://medical-tribune.co.jp/news/2021/0902538229/)

2.EurekAlert (https://www.eurekalert.org/news-releases/927204)

3.Asia RESEARCHNEWS(-https://www.asiaresearchnews.com/content/new-therapeutic-method-combined-synthetic-cd)

4.Hokkoku Shimbun Kanazawa University latest Research News(-https://www.kanazawa-u.ac.jp/latest-research/95792).